GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » CanSino Biologics Inc (HKSE:06185) » Definitions » Scaled Net Operating Assets

CanSino Biologics (HKSE:06185) Scaled Net Operating Assets : 0.34 (As of Mar. 2024)


View and export this data going back to 2019. Start your Free Trial

What is CanSino Biologics Scaled Net Operating Assets?

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

CanSino Biologics's operating assets for the quarter that ended in Mar. 2024 was HK$4,946.9 Mil. CanSino Biologics's operating liabilities for the quarter that ended in Mar. 2024 was HK$1,460.5 Mil. CanSino Biologics's Total Assets for the quarter that ended in Dec. 2023 was HK$10,192.7 Mil. Therefore, CanSino Biologics's scaled net operating assets (SNOA) for the quarter that ended in Mar. 2024 was 0.34.


CanSino Biologics Scaled Net Operating Assets Historical Data

The historical data trend for CanSino Biologics's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CanSino Biologics Scaled Net Operating Assets Chart

CanSino Biologics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Scaled Net Operating Assets
Get a 7-Day Free Trial 1.09 0.66 0.33 0.31 0.33

CanSino Biologics Quarterly Data
Dec16 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Scaled Net Operating Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 0.34 0.41 0.34

Competitive Comparison of CanSino Biologics's Scaled Net Operating Assets

For the Drug Manufacturers - Specialty & Generic subindustry, CanSino Biologics's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CanSino Biologics's Scaled Net Operating Assets Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, CanSino Biologics's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where CanSino Biologics's Scaled Net Operating Assets falls into.



CanSino Biologics Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

CanSino Biologics's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2023 is calculated as

Scaled Net Operating Assets (SNOA)(A: Dec. 2023 )
=(Operating Assets (A: Dec. 2023 )-Operating Liabilities (A: Dec. 2023 ))/Total Assets (A: Dec. 2022 )
=(5686.342-1455.834)/12807.556
=0.33

where

Operating Assets(A: Dec. 2023 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=10192.673 - 4506.331
=5686.342

Operating Liabilities(A: Dec. 2023 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=4409.41 - 1357.208 - 1596.368
=1455.834

CanSino Biologics's Scaled Net Operating Assets (SNOA) for the quarter that ended in Mar. 2024 is calculated as

Scaled Net Operating Assets (SNOA)(Q: Mar. 2024 )
=(Operating Assets (Q: Mar. 2024 )-Operating Liabilities (Q: Mar. 2024 ))/Total Assets (Q: Dec. 2023 )
=(4946.909-1460.507)/10192.673
=0.34

where

Operating Assets(Q: Mar. 2024 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=9308.183 - 4361.274
=4946.909

Operating Liabilities(Q: Mar. 2024 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=3760.982 - 1263.03 - 1037.445
=1460.507

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


CanSino Biologics Scaled Net Operating Assets Related Terms

Thank you for viewing the detailed overview of CanSino Biologics's Scaled Net Operating Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


CanSino Biologics (HKSE:06185) Business Description

Traded in Other Exchanges
Address
185 South Avenue, 401-420, 4th Floor, Biomedical Park, TEDA West District, Tianjin, CHN
CanSino Biologics Inc is a China-based company engaged in the research and development, manufacturing and commercialization of vaccine products for human use. These include products such as pneumococcal polysaccharide and conjugate vaccines as well as a DTcP-based combo and other items. At the same time, the group is also dedicated to the development of new vaccine-like recombinant adenovirus vector-based tuberculosis vaccines and a recombinant protein-based pneumococcal vaccine. Geographically, the activities are carried out through China.
Executives
The Capital Group Companies, Inc. 2201 Interest of corporation controlled by you
Jpmorgan Chase & Co.
Citigroup Inc.
The Goldman Sachs Group, Inc. 2201 Interest of corporation controlled by you
Blackrock, Inc. 2201 Interest of corporation controlled by you
Mao Helen Huihua 2201 Interest of corporation controlled by you
Qiming Corporate Gp Iv, Ltd. 2201 Interest of corporation controlled by you
Qiming Gp Iv, L.p. 2201 Interest of corporation controlled by you
Qiming Venture Partners Iv, L.p. 2201 Interest of corporation controlled by you
Qm29 Limited 2101 Beneficial owner
Qiu Dongxu 2501 Other
Yu Xuefeng 2501 Other
Zhu Tao
Chao Shou Bai 2202 Interest of your spouse
Orbimed Capital Llc 2102 Investment manager

CanSino Biologics (HKSE:06185) Headlines

No Headlines